{"entity":{"id":"nampt-inhibitor-payloads","kind":"term","name":"NAMPT inhibitor payloads","aka":["NAD depletion payloads","nicotinamide phosphoribosyltransferase inhibitor payloads"],"tldr":"These payloads cut off a supply route for a molecule cells need to keep their metabolism working. Antibody delivery is being studied to direct that effect toward tumors.","summary":"NAMPT inhibitors interfere with nicotinamide adenine dinucleotide, or NAD, salvage. Anti-c-KIT conjugates showed target-dependent efficacy in a gastrointestinal stromal tumor xenograft study. A later primary study examined physicochemical and metabolic optimization of NAMPT inhibitor conjugates for blood and solid tumor models. These are preclinical payload studies; the dependence of healthy tissues on NAD makes selective delivery and tolerability central questions.","asOf":"2026-11-08","links":[{"label":"Karpov et al., NAMPT inhibitors as conjugate payloads (2018)","url":"https://doi.org/10.1021/acsmedchemlett.8b00254"},{"label":"Ruedas et al., NAMPT payload optimization (2026)","url":"https://doi.org/10.1021/acsbiomedchemau.6c00047"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/nampt-inhibitor-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}]}}